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olga Genilloud1, Francisca Vicente1, Octavio caba3,4,5,6 & José pérez del palacio1,6
Colorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are 
urgently needed for its early diagnosis and treatment. the utilization of metabolomics to identify 
and quantify metabolites in body fluids may allow the detection of changes in their concentrations 
that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic 
targets. Metabolomics generates a pathophysiological ‘fingerprint’ that is unique to each individual. 
The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal 
cancer. Serum samples from 60 healthy controls and 65 patients with metastatic colorectal cancer were 
studied by liquid chromatography coupled to high-resolution mass spectrometry in an untargeted 
metabolomic approach. Multivariate analysis revealed a separation between patients with metastatic 
colorectal cancer and healthy controls, who significantly differed in serum concentrations of one 
endocannabinoid, two glycerophospholipids, and two sphingolipids. These findings demonstrate that 
metabolomics using liquid-chromatography coupled to high-resolution mass spectrometry offers a 
potent diagnostic tool for metastatic colorectal cancer.
Colorectal cancer (CRC) is still one of the main causes of cancer death1. Its pathogenesis has been well charac-
terized, and its development follows a sequence of stages from the transformation of normal colonic epithelium 
to an adenomatous intermediate polyp and then to an adenocarcinoma2,3. Tumor progression involves multiple 
genetic and epigenetic events, alongside environmental factors. Re-programming of cellular energy metabolism 
to support continuous cell growth and proliferation has also emerged as a hallmark of CRC4. In addition, numer-
ous metabolic enzymes are known to be altered when oncogenes (e.g. RAS, PTEN) or oncogenic transcription 
factors (e.g. p53, HIF) are affected by mutations. These altered genes produce a chain of metabolic events that 
can affect glycolytic flux, ATP sources, Krebs cycle and lipid metabolism, among others5, and there is abundant 
evidence of a strong association between lipid metabolism and CRC6.
Screening for CRC is essential to reduce its incidence and mortality, but the most reliable method, colo-
noscopy, is not only invasive but also requires highly specialized practitioners, expensive instrumentation, and 
specific installations; therefore, it is not always available in settings with limited resources7. Intense efforts are 
warranted to identify new biomarkers of CRC that could overcome these drawbacks. Currently, carbohydrate 
antigen 19-9 (CA-19-9) is the biomarker of choice to predict CRC8.
Metabolomics is a powerful tool that assesses concentrations of low-molecular weight molecules in biological 
matrices and can be used to generate “metabolic fingerprints” of individuals and diseases. The sensitivity and met-
abolic coverage of this process has been increased by combining metabolomics with high-resolution mass spec-
trometry9. Such studies have demonstrated an altered metabolism10,11 in CRC tissues in comparison to normal 
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mucosa, and studies combining proteomics and metabolomics have described a high rate of aerobic glycolysis in 
CRC11,12. Disorders in several metabolic pathways (fatty acid biosynthesis and oxidative, glycolytic, polyamine 
pathways, etc.) have also been reported in this disease13. However, despite this evidence of metabolic aberrations 
associated with CRC14, it has not proven possible to establish a metabolic profile to serve as a biomarker.
The aim of the present study was to identify potential biomarkers of metastatic CRC by using an untar-
geted metabolomics approach in serum samples from patients with metastatic CRC and healthy controls using 
reverse-phase liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS). The data 
matrix obtained from these samples showed a significant distinction between HC and CRC groups.
Methods
Sample collection. The study included blood samples from 65 patients with metastatic CRC (CRC group) 
and 60 healthy controls (HC group) matched with the CRC group for age and sex; the median age was 59.9 years 
in the CRC group, formed by 36 men and 29 women, and 56.1 years in the HC group, formed by 29 men and 
31 women. All patients were diagnosed with stage IV disease, without resection of the primary tumor, and liver 
and/or lung metastasis. Determination of overall survival was carried out (Supporting Information Fig. S1). The 
variation of different parameters regarding patients and sampling (fasting state, time of day of sampling, etc.) was 
minimize to obtain the maximum reproducibility in our study. In this way, fasting blood samples were drawn 
from the patients in hospital between 8 am and 9 am, before the initiation of any treatment and after obtaining 
written informed consent to participation in the study. The study was approved by the ethics committee of the 
Virgen de las Nieves Hospital (Granada, Spain), and all clinical investigations were conducted according to the 
principles expressed in the Declaration of Helsinki (“Ethical Principles for Medical Research Involving Human 
Subjects”). Samples were collected in BD vacutainer SSTII advance tubes (Becton Dickinson, Franklin Lakes, NJ) 
with silica to activate clotting of the specimen. After centrifugation for 10 min at 2450 rpm, the supernatant was 
aspirated and immediately stored at −80 °C until analysis. Serum samples from the healthy controls were supplied 
by the Biobank of the Andalusian Public Health System and were obtained and treated in the same manner as the 
samples from patients.
Metabolite extraction. Serum samples were kept at 4 °C throughout their analysis. First, proteins were 
removed using acetonitrile (AcN) (1:8 sample/AcN) and agitating for 2 min, followed by centrifugation at 
15200 rpm for 10 min at 4 °C. The supernatant was then transferred to HPLC analytical vials and evaporated in a 
GeneVac HT-8 evaporator (Savant, Holbrook, NY). Dry residues were reconstituted in AcN/water [50:50] with 
0.1% formic acid followed by agitation for 1 min.
Lc-HRMS analysis. Extracted serum samples were analyzed using an Agilent 1290 LC system coupled to a 
Q-TOF 5600 (Triple Quadrupole Time-of-Flight) mass spectrometer (AB SCIEX, Concord, ON) using electros-
pray ionization in positive mode. Chromatographic separation was performed with an Atlantis T3 HPLC column 
(C18: 2.1 mm × 150 mm, 3 μm) (Waters Corporation, Milford, MA) kept at 25 °C, injecting 5 μL of sample. The 
mobile phase was 0.1% formic acid-90:10 water/AcN (eluent A) and 0.1% formic acid-90:10 AcN/water (eluent 
B). The elution gradient was: 0.00–0.50 min 1% eluent B, 0.50–11.00 min 99% eluent B, 11.00–15.50 min 99% 
eluent B, 15.50–15.60 min 1% eluent B, and 15.60–20.00 min 1% eluent B. The flow rate was 300 µL/min. The 
Q-TOF 5600 was operated using a TOF method, providing mass selection with high resolution in combina-
tion with information dependent acquisition (IDA), allowing fragmentation of the eight most intense ions and 
obtaining simultaneously full-scan HRMS and MS/MS data. Ion Source parameters and IDA conditions were: gas 
source 1: 50.00; gas source 2: 50.00; curtain gas: 45.00; temperature: 500.00 °C; ionspray voltage floating: 4500.00; 
TOF masses: Min = 80.0000 Da Max = 1600.0000 Da; accumulation time: 0.2500 sec, IDA accumulation time: 
0.1000 sec.
A precise mass calibration was performed automatically every 10 injections. Organic solvent (OS) samples 
and quality control (QC) samples were analyzed during the run sequence. QC samples were prepared by pooling 
an equal volume of all serum samples used in this study and were run every 10 injections to evaluate the stability 
and performance of the system. OS samples were run alongside QC samples to identify any impurities from the 
organic solvents or extraction procedure and to rule out carryover contamination.
Data set creation. PeakView software (version 1.0 with Formula Finder plug-in version 1.0, AB SCIEX, 
Concord, ON) was used to evaluate the retention time (RT) and mass/charge (m/z) variability of the experiment. 
MarkerView software (version 1.2.1, AB SCIEX, Concord, ON) was used to process raw LC-HRMS data, carrying 
out peak detection, alignment, and data filtering and determining the m/z ratio, RT, and ion peak area for each 
sample. Data mining was performed by the program algorithm in the RT range of 1–18 min, and the peak inten-
sity cutoff was set at 200 cps. Peak alignment was achieved using RT and m/z tolerances of 0.10 min and 10 ppm, 
respectively. A filter by “presence” was used to only retain masses appearing in at least 10 samples within the study 
groups. Next, monoisotopic peaks alone were considered to reduce mass redundancy and enhance selection of a 
true molecular feature. Finally, mass signals differentially expressed by the OS and case study samples (HC and 
CRC) were identified by applying an additional filtering procedure with fold change (<1.5) and t test (p > 0.05). 
This procedure eliminated the background and contaminants and preserved the true biological mass signals from 
LC-HRMS data. The following steps were carried out using the Metaboanalyst 3.0 Web Server.
Data pre-treatment. Normalization was performed using total area sums, mean centering scaling, and log 
transformation to transform the data matrix into a more Gaussian-type distribution.
Analytical validation and outlier detection. The quality of the analytical system performance was eval-
uated, and principal component analysis (PCA) was used to detect possible outliers. QC samples were displayed 
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on a PCA plot to assess the stability of the analytical system. Variables were removed from the data matrix if 
their reproducibility was inadequate (relative standard deviation [RSD] > 30% in QC samples) or if they were 
observed in <50% of QC samples. The goodness of fit (R2) and goodness of prediction (Q2) of the model were 
tested. In parallel, one outlier in CRC and four in HC were identified from Hotelling T2 ellipses in partial least 
squares-discriminant analysis (PLS-DA) despite attempts to modify the standardization method (data not 
shown). The elimination of outliers did not produce an increase in R2 or Q2 values.
Statistical analysis. The survival time of patients was determined by constructing a Kaplan-Meier curve 
using SPSS 19.0 software. The Student’s t-test was used to compare between HC and CRC groups, followed 
by application of the Benjamini-Hochberg false discovery rate (FDR) correction for multiple comparisons to 
minimize false positives. An FDR-corrected p value of 0.05 was considered the cutoff threshold for the t-test. 
Multivariate analysis was then performed to identify variables that discriminated between the group, combin-
ing PCA with PLS-DA. Selection of the features with highest discriminatory power was based on their variable 
importance in projection (VIP) score, which had to be >1, and on their fold change, which had to be <0.6–>1.5.
Biomarker identification. PeakView software (version 1.0 with Formula Finder plug-in version 1.0, AB 
SCIEX, Concord, ON) was used to estimate the elemental formula of selected marker compounds from accurate 
mass, isotopic clustering, and fragmentation patterns. Next, accurate mass queries were performed in compound 
databases (Metlin, Human Metabolome Database, Lipid Maps, PubChem, ChemSpider), and fragmentation pat-
terns were searched for in spectral databases (MassBank, NIST2014) for structural identification of the molecular 
formula. The identification of selected candidates was confirmed by comparison with the accurate mass, RT, and 
fragmentation pattern of authentic analytical standards.
Metabolite evaluation. The predictive performance of the selected variables was evaluated by calculating 
the area under the receiver-operating characteristic (ROC) curve. Univariate and multivariate ROC analyses were 
conducted to evaluate the clinical value of features as biomarkers either individually or in combination.
Results and Discussion
Lc-HRMS analysis. AcN was used for extraction in this study, because deproteinization with an OS is a 
critical step in untargeted metabolomics to avoid ion suppression, and more information about lipid species is 
obtained in comparison to methanol, the other widely used solvent15. LC-MS, selected as analytical platform 
in this study, has become the technique of choice in metabolomics because of its higher sensitivity and broader 
range of detectable metabolites in comparison to NMR, the first analytical platform used for the comprehensive 
measurement of metabolites in a biological sample16. The selection of chromatographic mode (reverse phase or 
HILIC) determines the class of compounds amenable to separation, and a reverse phase column was chosen to 
achieve the separation of medium-polar and non-polar metabolites15. Total ion chromatograms (TIC) of HC 
and CRC samples (Fig. 1) revealed a clear separation among: medium-polar metabolites (e.g., phospholipids, 
lysophospholipids, and steroids), eluted between minutes 6 and 14; very polar metabolites (e.g., some amino acids 
and sugars), eluted in the first 5 minutes and best separated using a HILIC column17; and non-polar metabolites, 
eluted between minutes 14 and 17. According to these findings, the chromatographic process was satisfactory and 
Figure 1. Representative LC-HRMS TIC of the serum sample from a healthy control (HC: black) and patient 
with CRC (CRC: red). There is a clear separation among: medium-polar metabolites, such as phospholipids, 
endocannabinoids, or steroids (6–14 min); very polar metabolites, including some amino acids or sugars 
(1–5 min); and non-polar metabolites. A significant difference between HC and CRC TICs can be observed at 
8–15 minutes, when most lipids elute.
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a significant difference between HC and CRC TICs was observed between minutes 8 and 15, when most lipids 
elute18.
Other researchers have made similar efforts to characterize the metabolomic features of CRC, using different 
separation techniques and obtaining varying results19, but there has been little exploration of potential biomark-
ers of metastatic CRC. The results of metabolomic studies are influenced by numerous factors, including the sam-
ple type, analytical procedure, data treatment workflow, and cohort composition. There is a need to design novel 
metabolomic approaches to identify new biomarkers that offer an earlier diagnosis of metastatic CRC.
chemometric analysis. After alignment and filtering procedures, a data matrix of 4301 metabolite features 
was obtained, including 1868 monoisotopic peaks. Among these features, 1265 were differentially expressed in 
study samples (HC and CRC) and OS samples. After normalization, 99 features were excluded for unaccept-
able variability (RSD > 30%); therefore, 1166 variables were evaluated in the PCA. The PCA score plot (Fig. 2A) 
revealed a close clustering of QC samples, indicating that the separation observed between CRC and HC was 
mainly due to biological factors. Additionally, the PLS-DA score plot (Fig. 2B) suggested that it might be possible 
to discriminate between CRC and HC.
The predictive ability of the PLS-DA model to discriminate between CRC and HC was evaluated, adopting the 
criteria for success of R2 ≥ 0.7 and Q2 ≥ 0.4, with no variation >0.2–0.321. The present model obtained an R2 of 
0.74 and Q2 of 0.54, demonstrating its suitability for discriminating between HC and CRC samples. Five variables 
met the criteria established for potential biomarkers of metastatic CRC (FDR-corrected p < 0.05, VIP >1, and 
fold change >1.5) (Table 1).
Identification of potential biomarkers. Queries of accurate mass values in compound databases (Metlin, 
NIST, LipidMaps and Human Metabolome Database) provided several matches with a mass error below 5 ppm. 
Evaluation of the molecular formula from accurate mass and isotopic clustering provided a tentative identifica-
tion of each potential biomarker (Table 1). In addition, interpretation of the experimental fragmentation spec-
tra and comparisons in spectral databases allowed characteristic ions of certain compounds to be recognized. 
Five compounds were identified in three classes of lipids: sphingolipids (sphinganine, Galα1-3(Fucα1-2)Galβ1-
4Glcβ-Cer(d18:1/16:0)), endocannabinoids (docosatetraenoylethanolamide [DEA]), and glycerophospholipids 
(PE 18:2(9Z,12Z)/0:0) and PC (18:1(9Z)/0:0)). RT and MS/MS spectra of candidate biomarkers were then com-
pared with their corresponding commercial standards in biological samples under the same analytical condi-
tions. The RT and fragmentation pattern were virtually identical between marker and standard in the cases of 
sphinganine (Fig. 3) and PC (18:1) (Fig. 4)., confirming the tentative identification of these metabolites. A slight 
difference in RT was observed between DEA and the corresponding standard but the fragmentation patterns were 
similar, suggesting that this metabolite could belong to the endocannabinoid family (Fig. 5). Unfortunately, no 
commercial authentic standards of Galα1-3 (Fucα1-2) Galβ1-4Glcβ-Cer (d18:1/16:0) or PE (18:2(9Z,12Z)/0:0 
were available, preventing their definitive identification.
Biomarker evaluation. The AUCs obtained in ROC analyses (Table 1) suggest that the five candidate 
metabolites might potentially serve as biomarkers of metastatic CRC. Following an approach frequently adopted 
in complex diseases (e.g., cancer or heart or neurological disease), the combination of individual markers in a 
multivariate model was used to develop a more reliable algorithm. As shown in Fig. 6A, the AUC for the final 
model was 0.857 (95% CI 0.757–0.940), indicating its strong discriminative power and supporting the value of 
these metabolites in screening for CRC.
Figure 2. 2D score plots of the PCA (A) and the PLS-DA (B) of the HC group (green) and the CRC group 
(red). PCA score plot revealed a close clustering of quality control (QC) samples (blue). The PLS-DA score plot 
suggests that it is possible to discriminate between CRC and HC.
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The corresponding confusion matrix (Fig. 6B) shows that 45 HC samples were classified correctly and 15 
incorrectly, while 52 CRC samples were classified correctly and 13 incorrectly.
Biological interpretation. The transformation of a normal cell into a tumor cell mediates through diverse 
metabolic pathways (e.g., glycolysis, Krebs cycle, urea cycle, osmoregulation, eicosanoid biosynthesis, lipid 
metabolism, etc.). This altered metabolism might allow us to find several molecules specifically expressed in 
CRC20. In this study, CRC samples revealed alterations in lipid species involved in endocannabinoid, sphingo-
lipid, and glycerophospholipid metabolisms.
Endocannabinoids are known to have many different functionalities in the gastrointestinal tract, specifically in 
the colon, and they have been reported to inhibit CRC cell proliferation, mainly via CB1 receptors21. In the pres-
ent study, endocannabinoid levels were lower in CRC samples than in HC samples, which may be explained by 
the overexpression in CRC of lipid metabolizing enzyme MAGL, a key enzyme in endocannabinoid metabolism. 
In this regard, MAGL knockdown models were found to have reduced tumor growth through cyclin D1 and/or 
Bcl-2 downregulation22.
Significant alterations were also observed in two sphingolipids: sphinganine and a neutral glycosphingolipid. 








(ppm) p value FDR
Fold
change* VIP AUC Tentative identification
302.3042a 10.12 C18H39NO2 0.5 4.00E-03 2.48E-02 1.81 1.01 0.61 Sphinganine
376.2571a 10.89 C24H41NO2 4.2 4.00E-04 4.14E-03 10.68 2.25 0.77 Endocannabinoid
398.2424 10.90 C58H107NO22 1.2 7.00E-04 7.02E-03 6.63 1.86 0.73 Galα1-3(Fucα1-2) Galβ1-4Glcβ-Cer(d18:1/16:0)
500.2724 11.56 C23H44NO7P 0.5 9.43E-10 3.05E-07 0.49 1.12 0.61 PE(18:2(9Z,12Z)/0:0)**
522.3451a 11.61 C26H52NO7P 0.6 6.00E-08 2.60E-06 0.58 1.22 0.64 PC (18:1(9Z)/0:0)**
Table 1. Detailed information on the potential biomarkers of metastatic CRC. Biomarkers were selected 
according to t test (FDR correction; p < 0.05), fold change (<0.6–>1.5) and VIP (>1) results. Their potential as 
clinical biomarkers was evaluated using the area under the receiver-operating characteristic curves. PeakView 
software was used to estimate molecular formulas. Accurate mass and MS/MS patterns allowed structural 
identification of the molecular formula. *Fold change expressed as the ratio of the two averages (HC/CRC). 
**PE(18:2(9Z,12Z)/0:0): 1-(9Z,12Z-Octadecadienoyl)-glycero-3-phosphoethanolamine; PC (18:1(9Z)/0:0): 
1-(9Z)-Octadecenoyl-sn-glycero-3-phosphocholine. aConfirmed with reference standards.
Figure 3. Representative chromatogram of m/z 302.3042 in a biological sample (A) and sphinganine standard 
(B) at 10.13 min. Characteristic MS/MS spectra of m/z 302.3042 in a biological sample (C) and sphinganine 
standard at 10.13 min, and fragment interpretation (D). MS/MS spectra reveal the characteristic fragmentation 
pattern of sphinganine. Fragment ions at m/z 284 and 266 have previously been described as a single 
dehydration and a double dehydration, respectively. It should be noted that the single dehydration product is 
much more abundant than the double dehydration product, which is also a characteristic pattern.
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has been reported that human CRC cell apoptosis is promoted by CerS inhibition or the application of cer-
amide analogues26. We therefore hypothesized that decreased sphinganine concentrations might be explained 
by increased CerS concentrations. Because neutral glycosphingolipids are produced from sphingoid bases, their 
concentrations are also decreased in CRC27. Sphingolipids, key components of biologic membranes, are involved 
in numerous processes related to tumor progression23,28 and have been found to inhibit the growth of cancer cells 
and induce their apoptosis29. Specifically, sphinganine was reported to induce apoptosis in colon cancer cells by 
arresting the cell cycle at G2/M phase30,31. Furthermore, this class of lipids is mediated in part by modulation of 
the WNT/β-catenin pathway, one of the most important altered pathways in CRC32. A downregulation of the 
aforementioned pathways would result from low concentrations of these sphingolipids, favoring metastasization. 
The interplay between ceramides and endocannabinoids also appears to be crucial for cancer progression, given 
that cannabinoids regulate sphingolipid metabolic pathways by promoting sphingomyelin depletion and mark-
edly increasing ceramide concentrations.
Finally, dysregulated choline metabolism has been associated with oncogenesis and tumor progression33. 
Various enzymes are involved in this alteration of choline pathways, including glycerophosphocholine phos-
phodiesterases (GDPDs)34. These enzymes cleave glycerophosphocholine (GPC) to form glycerol-3-phosphate 
and choline, and their overexpression has been described in cancer, driving tumor cell migration and metasta-
sis35–37. In addition, the silencing of GDPDs was found to increase GPC and PE concentrations38. Accordingly, 
Figure 4. Representative chromatogram of m/z 522.3451 in a biological sample (A) and PC (18:1) standard (B) 
at 11.75 min. Characteristic MS/MS spectra of m/z 522.3451 in a biological sample (C) and PC (18:1(9Z)/0:0) 
standard (D) at 11.75 min. Fragment interpretation revealed characteristic ions of phosphatidylcholines, such as 
m/z 104 and 184.
Figure 5. Overlay representation of fragmentation spectra of m/z 376.2571 in a biological sample (blue trace) 
and DEA standard (pink trace).
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increased levels of GDPDs in metastatic CRC would be associated with decreased levels of GPC and PE. 
Significantly altered GPC and PE species have previously been described in CRC6.
We highlight that none of the markers identified in this study have previously been related to CRC39 with the 
exception of LPC (18:1). Interestingly, a significant decrease in LPC (18:1) was observed in non-advanced CRC 
patients40 but an increase in our patients with metastatic CRC, suggesting that this metabolite may potentially be 
useful as a biomarker of the progression of this disease.
conclusions
In this study, LC-HRMS untargeted metabolomics was used to identify a molecular signature that discriminates 
between individuals with and without CRC, illustrating the potential of this approach for discovering biomarkers. 
These results contribute new insights into the molecular mechanism and signaling pathways of metastatic CRC 
and identify novel biomarkers of potential clinical relevance. Further research in larger studies and external vali-
dation is warranted to determine the clinical applicability of these metabolic biomarkers in the diagnosis of CRC.
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